The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 30, 2013
Filed:
Sep. 30, 2009
Alicia Santos Savio, Ciudad de la Habana, CU;
Osvaldo Reyes Acosta, Ciudad de la Habana, CU;
Haydee Geronimo Perez, Ciudad de la Habana, CU;
Hilda Elisa Garay Perez, Ciudad de la Habana, CU;
Yunier Rodriguez Alvarez, Ciudad de la Habana, CU;
Gerardo Enríque Guillen Nieto, Ciudad de la Habana, CU;
Alicia Santos Savio, Ciudad de la Habana, CU;
Osvaldo Reyes Acosta, Ciudad de la Habana, CU;
Haydee Geronimo Perez, Ciudad de la Habana, CU;
Hilda Elisa Garay Perez, Ciudad de la Habana, CU;
Yunier Rodriguez Alvarez, Ciudad de la Habana, CU;
Gerardo Enríque Guillen Nieto, Ciudad de la Habana, CU;
Centro de Ingenieria Genetica y Biotecnologia, Ciudad de La Habana, CU;
Abstract
The present invention is related to the field of molecular immunology, particularly to a peptide derived from the sequence of interleukine-15 (IL-15), wherein said peptide was optimized to inhibit the biological activity of this molecule. In the present invention, it is shown that this peptide inhibits IL-15-induced T cell proliferation, Tumor Necrosis Factor α (TNFα) induction and the expression of IL-8 and IL-6 by the IL-15 receptor α subunit (IL-15Rα), all these effects mediated by the binding of the peptide to the IL-15Rα. The invention is also related to the use of the peptide to treat pathologies where the abnormal expression of IL-15 or IL-15Rα is related to the course of the disease, such as rheumatoid arthritis (RA) and prostate cancer.